Bli medlem
Bli medlem

Du är här

2015-04-14

ThromboGenics NV: ThromboGenics and VIB launch New Oncology Company

Oncurious NV to develop TB-403 for Pediatric Brain Tumors

Leuven, April 14, 2015
- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical
company focused on developing and commercializing innovative ophthalmic
medicines, today announces the foundation ofOncurious NV
, a new oncology company that will develop TB-403 for the treatment of
pediatric brain tumors. VIB, a leading life sciences institute in Flanders
(Belgium), will become a shareholder alongside ThromboGenics in this new
oncology venture. ThromboGenics will be the majority shareholder.

TB-403 is a humanized monoclonal antibody against placental growth factor
(PlGF). PlGF is expressed in several types of cancer, including
medulloblastoma. High expression of the PlGF receptor neuropilin 1 has been
shown to correlate with poor overall survival. Medulloblastoma is a rare,
life-threatening brain tumor that mainly affects children.

Treatment with TB-403 in relevant animal models for medulloblastoma has
demonstrated beneficial effects on tumor growth and survival. The antibody
can potentially be used in other pediatric cancer indications, including
neuroblastoma.

In February 2013, a paper inCell
(Cell, 152, 1065-76, 2013) highlighted for the first time that PlGF plays a
vital role in the brain and that its expression is required for the growth
and spread of medulloblastoma. The paper was based on pre-clinical research
conducted by Prof Rakesh Jain from the Massachusetts General Hospital at
Harvard (Boston) and the team of Prof Peter Carmeliet from VIB/ KU Leuven.

Oncurious now plans to start a Phase I/IIa program with TB-403 in
medulloblastoma patients. Enrollment of the first patient is expected for the
end of 2015.

The favorable safety profile of TB-403 has already been demonstrated in
clinical trials in patients with other diseases.

Dr Patrik De Haes, CEO of ThromboGenics
said,"The formation of Oncurious is an important development for
ThromboGenics,
which will allow us to even more focus our efforts on achieving our goals in
the ophthalmology space. This new venture should also enable an acceleration
of the development of TB-403 for the treatment of medulloblastoma, a
devastating cancer that affects children and adolescents. I would like to
thank VIB for supporting us in this new venture and for providing access to
exciting basic research that, in time, will allow Oncurious to build an
oncology pipeline."

Johan Cardoen, Managing Director of VIB
said,"We are excited that we can jointly translate the potential of VIB
research by
Prof. Peter Carmeliet into a reality for patients. We believe that TB-403 has
the potential to greatly improve the treatment of medulloblastoma and a
number of other pediatric tumours, an area of great medical need. This
collaboration illustrates the value of excellence-driven basic research at
VIB and ThromboGenics, and the pro-active approach to "make the difference
for patients". We are confident that together with ThromboGenics, we can
develop Oncurious into a leading oncology
company."
BioInvent International AB will act as a co-development partner for this
oncology project.

ThromboGenics has retained the exclusive license for use of TB-403 in
ophthalmic indications.

Ends

For further information please contact:

------------------------------------------------------------------------------------------------------------------
| ThromboGenics VIB |
| |
| |
|Wouter Piepers, Global Head of Corporate Communications&Investor Relations Johan Cardoen, Managing Director VIB |
| |
|+32 16 75 13 10 / +32 478 33 56 32 +32 9 244 66 11 / +32 475 98 45 25 |
| |
|wouter.piepers@thrombogenics.com Johan.Cardoen@vib.be |
------------------------------------------------------------------------------------------------------------------

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic and oncology medicines. The
Company's lead product, JETREA®(ocriplasmin), has been approved by the US FDA
for the treatment of symptomatic VMA and was launched in January 2013.

ThromboGenics signed a strategic partnership with Alcon, a division of
Novartis, for the commercialization of JETREA®outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin,
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext
Brussels exchange under the symbol THR. More information is available
atwww.thrombogenics.com.

About VIB

VIB is an excellence-driven life sciences research institute in Flanders,
Belgium. VIB aims to push the limits of our understanding of molecular
mechanisms of life and disease and provides a stimulating environment to its
scientists. VIB unites the expertise of 1400 scientists originating from over
60 countries in a single institute. Since its inception VIB is also an
entrepreneurial biotechnology catalyst focusing on translating basic
scientific breakthroughs into pharmaceutical, agricultural and industrial
applications. In this context, VIB pro-actively translates biological
insights into proof-of-concept stage assets which can be the basis for active
partnering with industrial players or the launch of new Venture
Capital-backed biotechnology companies. VIB also actively engages in the
public debate on biotechnology by developing and disseminating a wide range
of science-based information about all aspects of biotechnology. VIB has a
close partnership with four Flemish universities - Ghent University, KU
Leuven, University of Antwerp, and Vrije Universiteit Brussel. More
infowww.vib.be.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties.
The Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks
and uncertainties affecting the business and other factors that could cause
actual results to differ materially from any forward-looking statement is
contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction. No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ThromboGenics NV via Globenewswire

HUG#1910754

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.